Medivir has announced that the Board of Directors has tasked the company management with reviewing the possibility of dividing the company’s operations into two independent companies and achieving a separate listing for the commercial pharmaceutical portfolio.
The Board believes that a division of Medivir’s operations into a dedicated research and development company and a commercial pharmaceutical company could be advantageous for the company’s shareholders. The objective is to highlight the value of both the commercial operations and the pharmaceutical projects that make up the R&D portfolio. In addition, the split would enable the existing operations to be conducted by two clearly focused, specialised companies where both companies’ potential can be maximised in line with their different prerequisites and preconditions. The Board has, therefore, tasked the management with investigating these opportunities in further detail.
Carnegie Investment Bank and the law firm Vinge have been engaged as advisors for the process.